Independent Proxy Advisory Firm Glass Lewis Joins ISS In Recommending Advaxis Stockholders Vote "FOR" Proposed Merger With Biosight

Author: Benzinga Newsdesk | November 18, 2021 09:17am

Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that leading independent proxy advisory firm, Glass Lewis & Co. (Glass Lewis), joins Institutional Shareholder Services (ISS) in recommending that Advaxis stockholders vote "FOR" the stockholder proposals relating to the Company's proposed merger with Biosight.
 

In its report dated November 11, 2021, Glass Lewis stated1:

• We believe the strategic rationale for the proposed transaction is generally reasonable from the perspective of Advaxis shareholders.
  
  
   
• We find that the analyses presented by the advisor are reasonable and contain adequate disclosure. In particular, we note from the advisor's Comparable Initial Public Offerings Analysis that the implied value of the proposed consideration for Biosight ($218 million) falls within the fair value range derived by the advisor using pre-money equity values observed in seven IPOs involving Phase 2 companies without completing a crossover financing ($187 million to $406 million) and well below the range derived using equity values observed in 12 IPOs involving Phase 2 companies with a focus on oncology ($648 million to $819 million).
  
  
   
• Overall, we see no cause for significant shareholder concern with the strategic rationale or financial aspects of the proposed transaction, which would allow Advaxis shareholders to benefit from the development pipeline and stronger financial position of the combined company.
  
  
   
• Based on the forgoing factors and the support of the board, we believe the proposed transaction is in the best interests of shareholders.
   

Commenting on the reports, Kenneth A. Berlin, President, Chief Executive Officer and Interim Chief Financial Officer of Advaxis, said, "We are pleased that both Glass Lewis and ISS support our proposed combination with Biosight and recommend that Advaxis shareholders vote "FOR" the stockholder proposals relating to the merger. Our Board, which unanimously approved this transaction, is confident that merging with Biosight will create a well capitalized and better-positioned Company to advance a broader portfolio of drug candidates aimed at addressing both liquid and solid tumors. We strongly urge all Advaxis stockholders to follow the recommendations of ISS and Glass Lewis and vote "FOR" the shareholder proposals relating to the proposed combination with Biosight."

The Special Meeting, initially held on November 16, 2021, has been adjourned to December 7, 2021 at 10:00 AM Eastern Time unless postponed or adjourned to a later date, in order to obtain the stockholder approvals necessary to complete the merger and related matters. Advaxis stockholders will be able to attend and participate in the Advaxis special meeting online by visiting www.virtualshareholdermeeting.com/ADXS2021SM where they will be able to listen to the meeting live, submit questions and vote.

Posted In: ADXS